EB-DUALNK

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameEB-DUALNK
Drug Alias NameDual-Target CAR-NK Cells therapy (Beijing Biotech)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionNatural killer cell replacementsDisialoganglioside GD2 modulatorsMucin-16 modulators +[5] 
TargetsDisialoganglioside GD2Mucin-16Prostate-Specific Membrane Antigen +[4] 
Therapy Area/IndicationsFallopian Tube NeoplasmsPeritoneal NeoplasmsCarcinoma, Ovarian Epithelial
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Biotech
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Biotech
Inactive CompaniesN/A
Active IndicationsFallopian Tube NeoplasmsPeritoneal NeoplasmsCarcinoma, Ovarian Epithelial
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A